Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences’ Resilia Tissue

Key Takeaways

• 97.9% freedom from structural valve deterioration at 10 years
• 97.8% freedom from reoperation due to valve deterioration
• 98.6% freedom from non‑structural valve dysfunction
• RESILIA tissue resists calcification, extending valve lifespan for younger patients

Pulse Analysis

The durability of bioprosthetic aortic valves has long been a limiting factor for younger patients, who face higher risks of structural valve deterioration (SVD). As clinicians move toward earlier intervention in aortic stenosis, robust long‑term data become essential for guiding heart‑team decisions. Edwards Lifesciences’ 10‑year COMMENCE trial fills this gap by delivering prospective evidence that its RESILIA tissue can sustain performance well beyond the typical five‑year benchmark, offering a compelling alternative to mechanical valves for a broader age range.

RESILIA’s proprietary calcium‑blocking process and dry‑storage technology are engineered to mitigate the calcification that drives most valve failures. The trial, an FDA‑approved, multicenter study, tracked over 500 patients with surgical aortic valve replacement (SAVR) using RESILIA tissue. Results showed 97.9% freedom from SVD, 97.8% freedom from reoperation, and 98.6% freedom from non‑structural dysfunction, alongside stable gradients and effective orifice areas. These outcomes align with, and in some respects exceed, durability metrics from earlier PARTNER series trials, suggesting that RESILIA may set a new standard for bioprosthetic longevity.

For the cardiac device market, the findings signal a shift toward durable tissue solutions that can compete with mechanical options without the need for lifelong anticoagulation. Hospitals and surgeons can anticipate reduced repeat‑procedure volumes, while payers may see lower long‑term costs. Edwards’ ability to generate and publish decade‑long data strengthens its credibility with regulators and clinicians, positioning the company to capture growth in both surgical and transcatheter valve segments as patient expectations for lifetime care evolve.